Christophe Severin

Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab

M. Merchant, E. Filvaroff, I. Nijem, 2013, Molecular Cancer Therapeutics.

Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Somasekar Seshagiri, Jeremy Stinson, S. Seshagiri, 2006, Cancer research.

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).

J. Veal, D. Hosfield, L. Lawton, 2020, Journal of medicinal chemistry.

556 POSTER MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models

G. Woude, E. Filvaroff, Zhong Zheng, 2008 .

Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors

J. Zha, G. Woude, M. Romero, 2008 .

Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.

J. Veal, Jiangchun Xu, J. D. Del Rosario, 2019, Bioorganic & medicinal chemistry letters.